国际并跑水平！以岭药业通心络重磅论文发表，获稳定斑块高质量循证证据

Core Viewpoint - The study published in the journal "Signal Transduction and Targeted Therapy" demonstrates that the combination of Tongxinluo capsules with standard treatments significantly improves the stability of vulnerable coronary plaques in patients with acute coronary syndrome, providing an effective therapeutic option for clinical management [1][4]. Group 1: Study Overview - The study titled "Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Clinical Study on the Intervention of Tongxinluo Capsules in Acute Coronary Syndrome Coronary Atherosclerotic Plaques" was published on February 24 and is part of a national key research project [2]. - The research was led by a team from Shandong University and involved 17 top-tier hospitals across China, focusing on whether Tongxinluo can further stabilize vulnerable coronary plaques in addition to standard treatments [2][3]. Group 2: Study Methodology - A total of 1,607 patients with acute coronary syndrome underwent Optical Coherence Tomography (OCT) examinations, from which 220 patients were selected and randomly assigned to either the Tongxinluo group or the control group [3]. - All selected patients had unstable coronary plaques and received recommended interventional and standard drug treatments, with approximately 93% of patients in both groups using statins [3]. Group 3: Study Results - After 12 months of treatment, the Tongxinluo group showed an average increase in fibrous cap thickness of 61.2 micrometers, compared to 33.7 micrometers in the control group, indicating nearly double the effectiveness [4]. - The maximum lipid arc in the Tongxinluo group decreased by approximately -38 degrees, significantly more than the -8 degrees reduction in the control group, suggesting enhanced plaque stability [4]. - The study also reported significant improvement in angina symptoms for the Tongxinluo group, with good safety profiles [4]. Group 4: Clinical Evidence - Previous studies led by Professor Yang Yuejin confirmed that continuous use of Tongxinluo for 12 months significantly improves clinical outcomes and reduces the risk of major adverse cardiovascular events in patients with ST-segment elevation myocardial infarction [5]. - The accumulating clinical evidence supports the unique value and application prospects of traditional Chinese medicine, particularly Tongxinluo, in the standardized treatment and comprehensive management of acute coronary syndrome [5].